| Methods |
Cluster‐randomisation by households, open, no loss to f/u |
| Participants |
Household contacts, Malawi |
| Interventions |
Rifampicin: 2 to 18 years 4 x 20 mg/kg; > 18 years 4 x 600 mg
versus
single‐dose ciprofloxacin: 2 to 18 years 1 x 15 mg/kg for 2 to 18 years; > 18 years 1 x 750 mg
versus
IM ceftriaxone: pregnant women 2 g; < 2 years 50 mg/kg |
| Outcomes |
Morbidity, eradication, re‐acquisition, adverse effects
Follow‐up: 2 weeks |
| Notes |
Data presented for carriers. Main serogroups: A W135. Ceftriaxone group not randomised and not included in analysis |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
Unclear |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
Open |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
Open |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
No loss to f/u |
| Selective reporting (reporting bias) |
Low risk |
No evidence |
| Other bias |
Low risk |
No evidence |
